Aaron Koenig
Chief Medical Officer Delix Therapeutics
Seminars
Wednesday 16th September 2026
Chair’s Opening Remarks
7:50 am
Wednesday 16th September 2026
Panel Discussion: Overcoming the Phase 2/3 Roadblock in Neuropsychiatric Drug Development: What Have We Learnt in 2026?
8:00 am
- What recent Phase 2 and Phase 3 readouts have taught us about target validation in neuropsychiatric drug development?
- How can sponsors better address persistent challenges around placebo response, site quality and trial execution?
- To what extent do indication selection and patient population definitions influence the probability of success?
- How can biomarkers, precision psychiatry approaches and improved patient stratification help derisk future development programmes?
- What lessons from recent successes and setbacks should shape the next generation of neuropsychiatric clinical trials?
Wednesday 16th September 2026
Panel Discussion: What Tools Can Be Used to Demonstrate Efficacy Through Early-Stage Clinical Trials? Evaluating Digital Biomarkers, EEG, PROs & Fluid Measures to Support with a Richer Analysis of Disease State
3:00 pm
- How multimodal digital biomarkers can sensitively capture early treatment signals and behavioral change before traditional clinical endpoints emerge
- The role of EEG and other neurophysiological readouts in demonstrating target engagement and pharmacodynamic effects during first in human and Phase 1/2 trials
- How structured patient reported outcomes enrich early datasets by capturing subjective symptom shifts that complement objective biomarker trends
- How fluid biomarkers – from inflammatory to neurodegenerative signatures – can provide quantifiable, mechanistic insight into early biological response and disease modulation
Wednesday 16th September 2026
Panel Discussion: Future Directions & Strategic Investment to Fuel the Next Wave of Neuropsychiatric Therapeutics
4:30 pm
- How has investor sentiment evolved as neuropsychiatry moves from scientific validation toward commercial execution and scalability?
- What constitutes an attractive opportunity in today's investment landscape?
- How are investors evaluating next-generation psychedelic approaches, including non-hallucinogenic neuroplastogens and differentiated product profiles?
- Which emerging therapeutic areas and indications are generating the greatest excitement across neuropsychiatry?
- What scientific, clinical and commercial milestones are investors looking for before committing capital?
Wednesday 16th September 2026
Chair’s Closing Remarks
5:30 pm
Thursday 17th September 2026
Chair’s Opening Remarks
Thursday 17th September 2026
Chair’s Closing Remarks
4:05 pm
